NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...
SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...
